Page 16 - Read Online

Monge Bonilla et al. Hepatoma Res 2020;6:68 I http://dx.doi.org/10.20517/2394-5079.2020.58 Page 11 of 14

2. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, et al. Global burden of 5 major types of gastrointestinal cancer.
Gastroenterology 2020;159:335-49.e15.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
4. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, et al; HALT-C Trial Group. Incidence of hepatocellular carcinoma and
associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
6. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological
gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
7. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-
term predictors from a community-based cohort study. J Clin Oncol 2010;28:4587-93.
8. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, et al; Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma
in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-55.
9. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting
antiviral agents. Gastroenterology 2017;153:996-1005.e1.
10. Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision
medicine. J Hepatol 2018;68:526-49.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular
carcinoma. N Engl J Med 2008;359:378-90.
12. Kudo M, Finn RS, Qin S, Han K, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable
hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
13. Bruix J, Qin S, Merle P, Granito A, Huang Y, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib
treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
14. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
15. Zhu AX, Kang Y, Yen C, Finn RS, Galle PR, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma
and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2019;20:282-96.
16. Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with
melanoma. Cancer J 2012;18:153-9.
17. Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic
regulation of cccDNA function. Proc Natl Acad Sci U S A 2009;106:19975-9.
18. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, et al. Temporal analysis of early immune responses in patients with acute hepatitis B
virus infection. Gastroenterology 2009;137:1289-300.
19. Sato S, Li K, Kameyama T, Hayashi T, Ishida Y, et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral
factor for hepatitis B virus. Immunity 2015;42:123-32.
20. Shlomai A, Schwartz RE, Ramanan V, Bhatta A, de Jong YP, et al. Modeling host interactions with hepatitis B virus using primary and
induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci U S A 2014;111:12193-8.
21. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in
acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus
infections. J Virol 2009;83:3719-33.
22. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci
U S A 2004;101:6669-74.
23. Boltjes A, van Montfoort N, Biesta PJ, Op den Brouw ML, Kwekkeboom J, et al. Kupffer cells interact with hepatitis B surface antigen in
vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function. J Infect Dis 2015;211:1268-78.
24. Wu J, Meng Z, Jiang M, Pei R, Trippler M, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in
murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49:1132-40.
25. Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN, et al. TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp
Med 2008;205:233-44.
26. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus
infection. Gut 2009;58:974-82.
27. Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, et al. Compromised function of natural killer cells in acute and chronic viral
hepatitis. J Infect Dis 2014;209:1362-73.
28. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, et al. Natural killer cell functional dichotomy in chronic hepatitis B and
chronic hepatitis C virus infections. Gastroenterology 2009;137:1151-60, 1160.e1-7.
29. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, et al. The size of the viral inoculum contributes to the outcome of
hepatitis B virus infection. J Virol 2009;83:9652-62.
30. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29.
31. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral
hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8.